Shots:

• The P-III NAVIGATOR study involves assessing Tezepelumab + SOC vs PBO + SOC in 1061 adults (18–80yrs.) & adolescents (12–17yrs.) with severe- uncontrolled asthma- who were receiving treatment with medium/high dose ICS + at least 1 additional controller medication with/ out OCS
• The trial met its 1EPs i.e. 56% reduction in AAER @52wks. in the overall population. The study also met 1EPs in the subgroup of patients with low levels of eosinophils i.e. 41% & 39% reduction with <300 & 150 cells/microlitre respectively
• Tezepelumab is mAb that inhibits the action of TSLP and has received US FDA’s BT designation in Sept’2018 for patients with severe asthma- without an eosinophilic phenotype

 ­ Ref: Amgen | Image: The Scientist Magazine